The QualityStocks Daily Wednesday, July 24th, 2019

Today's Top 3 Investment Newsletters

Planet Penny Stocks (FPPP) +274.29%

QualityStocks (ZZZOF) +129.67%

StockMarketWatch (AMRWW) +81.82%

The QualityStocks Daily Stock List

Comepay, Inc. (CMPY)

Stockhouse, InvestorsHub, Business Insider, and Nasdaq reported previously on Comepay, Inc. (CMPY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Comepay, Inc. provides Internet acquiring and support services. In addition, the Company engages in facilitating instant payments and internet based payment transactions by way of kiosks, mobile interfaces, and Web-based applications. The Comepay group of companies includes Comepay, RP Systems, M-NN LLC, and Chek-Online. Comepay is based in Vaughan, Ontario and the Company lists on the OTC Markets.

Comepay also leases and sells cash registers and point of sale (POS) systems. This includes its recently developed proprietary multifunctional smart POS fiscal cash register system. The Company processes greater than 4.7 million customer payments per month. Currently, Comepay has more than 12,700 kiosks across Russia.

The aforementioned companies are now focusing their planned business expansion on the smart POS fiscal cash register system "Cassatka". This is to help businesses comply with Russian taxation legislation, 54-FZ, which required 1.2 million businesses in fiscal 2018, and a further 1.4 million businesses in fiscal 2019 to install new, federally compliant on-line cash registers.

The Cassatka is Comepay's multifunctional smart POS online fiscal cash register. Cassatka can process payments and meet fiscal data storage requirements for participating businesses. Cassatka is a convenient and cost competitive solution for businesses to meet the new federal taxation requirements in Russia.

Comepay expects to offer blockchain acquiring services and to accept payments in many crypto currencies on the Cassatka. This is as the companies expand their business model. The Comepay group of companies presently earn revenue from a host of channels. These include fee-based commissions on payment processing for cash and debit card payments, software licensing, kiosk placement fees and other rental fees for cash registers and associated equipment.

Comepay’s wholly-owned subsidiary, Chek-Online LLC, has again added more functionality to its smart terminals through integrating merchant acquiring services from two large banks in Russia for its versatile handheld Cassatka-Mini terminal. Chek-Online is a top manufacturer of fiscal cash registers in Russia, and the developer of the family of Cassatka smart terminals.

Last month, Comepay announced that Volkswagen Russia recently entered into agreements for the rental of fiscal cash registers at the Chek-Online data center to facilitate transactions processed from its website in compliance with Russian Federal tax legislation, 54-FZ, as required for all payments to individuals and corporate entities made electronically. The lease agreement for the fiscal cash registers includes the actual registers. In addition, it includes servicing and maintenance of the leased equipment, security and monitoring, support, installation and data storage and software integration. The Chek-Online fiscal cash registers provide Volkswagen with the ability to conduct a large number of transactions simultaneously, while producing online receipts and fiscal reporting in real time.

Recently, Comepay announced that Chek-Online started a cooperative project with Zolotaya Korona, the operator of “KoronaPay”, the largest payment system in Russia offering simple and convenient cash money transfer services used by millions of customers in Russia, CIS and globally. This project is to integrate the use of Zolotaya Korona transport cards with the Cassatka smart terminal, making the transport cards totally compliant with recent Russian tax legislation.

Comepay, Inc. (CMPY), closed Wednesday's trading session at $1.12, even for the day, on 13,962 volume with 38 trades. The average volume for the last 3 months is 11,507 and the stock's 52-week low/high is $0.319999992/$5.25.

chart

Leagold Mining Corporation (LMCNF)

OTC Markets, StreetWise Reports, Stockhouse, StockInvest.us, Northern Miner, InvestorsHub, Baystreet, News to Watch, Ceo.ca, Metals News, and 4-Traders reported previously on Leagold Mining Corporation (LMCNF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Leagold Mining Corporation is a mid-tier gold producer headquartered in Vancouver, British Columbia. The Company focuses on opportunities in Latin America. It formerly went by the name HTI Ventures Corp. It changed its name to Leagold Mining Corporation in August 2016. Leagold Mining lists on the OTC Markets Group’s OTCQX.

Leagold Mining owns four operating gold mines in Mexico and Brazil. In addition, the Company has an expansion opportunity in Mexico and a near-term gold mine restart project in Brazil. Leagold has an inventory of 7.1 million ounces of gold reserves from which to grow. Its operating mines are Los Filos, RDM, Fazenda, and Pilar. Its development projects are the Los Filos expansion and Santa Luz.

The expectation is that the Company’s four gold mines in Mexico and Brazil will collectively produce 380,000-420,000 oz gold in 2019 at an all-in sustaining cost (AISC) of $920-970/oz. In 2018, Leagold produced 302,550 oz gold – in line with guidance of 295,000- 305,000 oz.

Leagold Mining announced this past March that it filed the report entitled "Independent Technical Report for the Los Filos Mine Complex, Mexico " that presents the results of the Expansion Feasibility Study under its profile on SEDAR. The Expansion Feasibility Study was prepared by independent consultants.

The Expansion Feasibility Study incorporates the potential for development of the Bermejal underground mine, enlarging the Los Filos open pit, re-phasing of the Bermejal open pit into two distinct sections (Bermejal and Guadalupe), and building a carbon-in-leach (CIL) processing facility to complement the existing heap leach facilities. A highlight of the Expansion Feasibility Study is gold production of 3.2 million ounces (Moz) over a 10-year mine life (2019 to 2028) at an average AISC of $740/oz.

Recently, Leagold Mining announced it completed the earlier announced debt refinancing with a syndicate of lenders, which includes a $200 million term loan and a $200 million revolving credit facility. These loans have been used to replace $238 million of existing short-term debt. They will provide new financing for Leagold's growth via the phased expansion of the Los Filos mine complex and the construction of the Santa Luz project.

This month, Leagold Mining reported Q2 2019 consolidated gold production of 91,285 ounces (oz). This brings year to date 2019 production to 197,234 oz, which is in line with guidance. Sales in the first half of the year totalled 201,724 oz. Financial results and more production details for Q2 2019 will be reported on August 1, 2019 after the close of markets. A conference call and live webcast will follow on August 2, 2019 at 8am PDT/11am EDT.

Leagold Mining Corporation (LMCNF), closed Wednesday's trading session at $1.6843, up 0.255952%, on 82,309 volume with 121 trades. The average volume for the last 3 months is 83,582 and the stock's 52-week low/high is $0.949999988/$2.03159999.

chart

Abacus Health Products, Inc. (ABAHF)

New Cannabis Ventures, Penny Stock Hub, Cannanbindex.co, OTC Markets, InvestorX, Stockhouse, Dividend Investor, Stockwatch, TradingView, Investors Hangout, and Market Screener reported beforehand on Abacus Health Products, Inc. (ABAHF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Abacus Health Products, Inc. manufactures and sells over-the-counter (OTC) topical formulations infused with cannabidiol (CBD) extracted from hemp. The Company targets its products at the fast growing markets for topical pain relief and therapeutic skincare. Its products are based on proprietary patent-pending technologies developed by Abacus. OTCQX-listed, Abacus Health Products is a subsidiary of Aidance Skincare & Topical Solutions, LLC.

Abacus Health Products was created with a mission to use CBD hemp extract (Cannabis sativa L) as a conduit to deliver the world’s fastest and most effective pain relief products to millions of people throughout the world. Fundamentally, Abacus engages in the development and commercialization of OTC registered topical medications with active pharmaceutical ingredients. These contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD (cannabidiol) from the Cannabis sativa L plant.

At present, the Company offers two lines of products. One is CBD CLINIC™, marketed to the professional practitioner market. The other is CBDMEDIC™, marketed to the consumer market. Abacus' products are offered throughout the U.S. They are produced by a contract manufacturer in a cGMP compliant and audited manufacturing facility.

Abacus Health Products is the first company to secure OTC registrations for a suite of products blended with CBD hemp extract (Cannabis sativa L). The Company commenced distribution to healthcare practitioners in 2016 under the CBD CLINIC brand name. In Q3 2018, Abacus launched CBDMEDIC directly to the active fitness and mass retail markets.

CBD CLINIC products are formulated to support quick and lasting relief from joint and muscle pain. A proprietary blend of natural emollients facilitates deeper and speedier absorption of pain-relieving compounds to interrupt pain signaling. Moreover, the Company’s CBDMEDIC products use only naturally-derived analgesic ingredients and 100 percent natural oils to help hasten absorption. The CBDMEDIC line is segmented into three product categories. These are Active Sport, Back & Neck and Arthritis.

Last week, Abacus Health Products announced a new retail purchase order by Valu Merchandisers Company for its line of CBDMEDIC™ products. Valu Merchandisers confirmed an order with Abacus that will see 11 SKUs from the CBDMEDIC™ product line placed in 350 retail stores across six states, with expansion to greater than 1,000 locations over the next six months.

This new purchase order increases Abacus Health's total retailer store count to around 2,550 locations in 15 States across the U.S. Valu Merchandisers is a cooperative food distributor serving more than 3,800 independently-owned supermarkets in 30 U.S. States.

Abacus Health Products, Inc. (ABAHF), closed Wednesday's trading session at $6.38, off by 11.7566%, on 12,441 volume with 22 trades. The average volume for the last 3 months is 1,852 and the stock's 52-week low/high is $6.15000009/$14.00.

chart

AeroGrow International, Inc. (AERO)

Awesome Penny Stocks, Zacks, Last10k, Investing Daily, New Cannabis Ventures, TMX Money, Daily Marijuana Observer, Market Screener, Stockhouse, Stockwatch, Stockopedia, Wallet Investor, and GlobeNewswire reported previously on AeroGrow International, Inc. (AERO), and today we report on the Company, here at the QualityStocks Daily Newsletter.

AeroGrow International, Inc. engages in the development, marketing, direct-selling, and wholesale of indoor garden systems to consumers and retailers around the world. The Company is the manufacturer and distributor of AeroGardens – the world’s leading family of In-Home Garden Systems™. AeroGrow International, Inc. is a subsidiary of SMG Growing Media, Inc. Established in 2002, AeroGrow International has its head office in Boulder, Colorado.

AeroGrow International entered into a strategic partnership in April of 2013 with Scotts Miracle-Gro to continue to expand the indoor gardening market. The Company’s AeroGardens allow anyone to grow farmer’s market fresh herbs, salad greens, tomatoes, chili peppers, flowers and more, indoors, simply and easily. AeroGrow’s main products include indoor gardens and proprietary seed pod kits.

In addition, AeroGrow provides grow lights and a patented nutrient formula. The Company also provides diverse cooking, gardening, and decor accessories. It offers its in-home garden systems under the AeroGardens name. The Company’s products are used in the gardening, cooking, healthy eating, and home and office décor markets.

With the AeroGarden, plants grow in water 5x faster than in soil. No herbicides or pesticides are part of the process, and AeroGarden grows non-GMO seeds. Customers can grow plants year round.

Last month, AeroGrow International announced results for Q4 and for the Fiscal Year (FY) ended March 31, 2019. For Q4, the Company recorded Net Revenue of $9.1 million. This represents an increase of 35 percent over the same period in the prior year. Income from Operations was $524K. This is up considerably from $4K in the previous year.

For the year ended March 31, 2019, AeroGrow International recorded Total Revenue of $34.4 million. This represents an increase of 6 percent over the prior year. Income from Operations for the full year period was $6K. This is up from a loss of $448K in the previous year. FY 2019 represents the first time in AeroGrow’s history that it posted an Operating Profit.

AeroGrow International, Inc. (AERO), closed Wednesday's trading session at $1.41, off by 2.7586%, on 5,515 volume with 21 trades. The average volume for the last 3 months is 8,679 and the stock's 52-week low/high is $1.12/$3.40000009.

chart

DionyMed Brands, Inc. (DYMEF)

SmallCapPower, OTC Markets, Penny Stock Hub, Stockwatch, Stockhouse, GuruFocus, Investorx, Business Wire, Otc.Watch, Trading View, New Cannabis Ventures, Dividend Investor, and Investors Hangout reported earlier on DionyMed Brands, Inc. (DYMEF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, DionyMed Brands, Inc. is a multi-state cannabis brands and distribution platform. The Company supports cultivators, manufacturers and award-winning brands in the medical and adult-use cannabis markets. DionyMed sells branded products in every category from flower to vape cartridges, concentrates and edibles. Established in 2017, DionyMed Brands is based in Toronto, Ontario.

DionyMed serves cannabis consumers through retail dispensary distribution and direct-to-consumer fulfillment with its growing portfolio of award-winning brands. The Company has 12 wholly-owned brands. It serves greater than 800 dispensaries per month. In addition, DionyMed performs 1,500 Direct-to-Consumer Deliveries per day.

DionyMed has an expertly designed proprietary platform. The platform supports the design, development, distribution, and marketing of award-winning brands at scale. Pertaining to its brands, the Company has a growing product portfolio leveraging important market opportunities to develop leading brands. DionyMed’s brands include Winberry Farms, Gardener’s, Aja, and Afterglow. Its portfolio brands include Herbology, Fire King, Headwaters, HigherVeda Medicinals, GPen, Reveur, and Gio.

Concerning distribution, DionyMed has an industry-leading platform permitting end-to-end compliant delivery, sales, and cash logistics for brands, cultivators, and retailers. Moreover, the Company is the largest Direct-to-Consumer fulfillment provider. It has an extensible platform for D2C e-commerce. DionyMed’s services include Logistics Services & Software; Warehousing & Co-Packing; Value-Added Manufacturing; and Retail & Direct-to-Consumer Delivery.

Today, DionyMed Brands confirmed the official close of its earlier announced acquisition of select assets from MM Esperanza 2 LLC, doing business as “MMAC,” and MMAC’s 1.83 acre Los Angeles cannabis campus, including retail, distribution, manufacturing and cultivation licenses, for the purchase price of US$13,067,000 in cash and US$6 million in DionyMed Series A Multiple Voting Shares to MMAC.

In combination with the close of the MMAC transaction, DionyMed completed its sale-leaseback agreement with Innovative Industrial Properties, Inc. (NYSE: IIPR), to purchase the Los Angeles cannabis campus for US$13 million and to enter into a long-term lease back of 15 years with two optional 5-year extensions. Furthermore, IIPR is providing DionyMed up to US$2 million of capital to make improvements at this property.

Mr. Edward Fields, DionyMed Chief Executive Officer, said, “This acquisition strategically positions DionyMed as a leader in California’s cannabis market. By incorporating MMAC’s Southern California direct-to-consumer fulfillment center, distribution facility, manufacturing hub, cultivation facility and dispensary storefront, with our existing operational base in Northern California, DionyMed is positioned for long-term growth to serve the largest cannabis market in the country.”

DionyMed Brands, Inc. (DYMEF), closed Wednesday's trading session at $1.455, up 5.4348%, on 147,954 volume with 173 trades. The average volume for the last 3 months is 8,679 and the stock's 52-week low/high is $0.174999997/$3.21000003.

chart

Todos Medical Ltd. (TOMDF)

Stock News Now, TalkMarkets, InvestorsHub, Investors Hangout, Stockhouse, Otc.Watch, Wallet Investor, TradingView, GlobeNewswire, Market Screener, Stockopedia, and Proactive Investors reported earlier on Todos Medical Ltd. (TOMDF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Todos Medical Ltd. focuses on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease (AD). A clinical-stage in-vitro diagnostic company, it does so via Breakthrough Diagnostics, Inc., its joint venture (JV) with Amarantus Bioscience Holdings, Inc. Breakthrough Diagnostics is developing the Alzheimer’s blood diagnostic LymPro Test®. Todos Medical’s shares trade on the OTC Markets Group’s OTCQB. The Company is based in Rehovot, Israel.

Todos Medical has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses). This is a method for cancer screening using peripheral blood analysis. The TBIA screening method is founded on the cancer’s influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. The proprietary and patented method incorporates biochemistry, physics, as well as signal processing.

Todos Medical’s two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Its new cancer test will add a layer to presently available cancer screening and diagnostics. The company’s technology is a platform. Todos is investigating methods for using its platform on other kinds of cancers. Initially, Todos is centered on breast and colon cancers.

In essence, Todos Medical’s TBIA platform represents a cost effective, scalable, and patient friendly screening method for cancer screening. The TBIA method is a proprietary method for the screening of solid tumours utilizing peripheral blood spectroscopy analysis. This process involves observing the immune system’s response to tumor presence instead of looking for the tumor cells themselves or specific markers. TBIA analyzes the entire biochemical signatures spectrum (including proteins, lipids, nucleic acids and carbohydrates) of effected immune cells from peripheral blood, using infrared spectroscopy.

Last week, Todos Medical announced positive results from a pre-specified interim analysis of 20 subjects from a continuing 40-subject outpatient study evaluating the relationship between LymPro Test™ (LymPro) scores with amyloid PET imaging scores. LymPro measures cell cycle dysfunction in peripheral lymphocytes. The data revealed strong and statistically significant correlation between LymPro scores and amyloid PET neuroimaging cSUVR scores (r = -0.849; p = 0.00000216).

This study is being conducted under the direction of Dr. Thomas Arendt at the University of Leipzig in Germany, with mild cognitive impairment (MCI) and dementia patients evaluated in the clinic of the Neurobiological Research group in the Department of Psychiatry and Psychotherapy. Todos Medical expects the University of Leipzig to complete patient enrollment in the second half of 2019, and to disclose complete results in a future scientific conference. Todos Medical’s JV company, Breakthrough Diagnostics, is sponsoring the study.

Todos Medical Ltd. (TOMDF), closed Wednesday's trading session at $0.32, up 6.6667%, on 39,894 volume with 12 trades. The average volume for the last 3 months is 9,726 and the stock's 52-week low/high is $0.05/$0.319999992.

chart

Vireo Health International, Inc. (VREOF)

New Cannabis Ventures, Born2Invest, Midas Letter, Stock Target Advisor, Investing.com, Insider Financial, InvestorsHub, Investorideas, Stockwatch, Stockhouse, NIC Investors, PR Newswire, Market Screener, and TradingView reported beforehand on Vireo Health International, Inc. (VREOF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Vireo Health International, Inc. is a foremost science-focused, multi-state cannabis company listed on the OTC Markets. The Company’s mission is to build the cannabis company of the future through bringing the best of medicine, engineering, as well as science to the cannabis industry. At present, Vireo is licensed in eleven states and territories. These comprise Arizona, Maryland, Massachusetts, Minnesota, Nevada, New Mexico, New York, Ohio, Pennsylvania, Puerto Rico and Rhode Island. Vireo Health International has its corporate office in Minneapolis, Minnesota. Vireo Health of New York is a subsidiary of Vireo Health International.

The Company’s physician-led team of over 350 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at company-owned and third-party dispensaries.

Vireo Health integrates best-in-class medical, scientific, and engineering practices into the cannabis industry. The Company’s dedication is to creating safe, all-natural cannabis-based products and a compassionate patient experience. Vireo cultivates cannabis in their environmentally friendly greenhouses and manufactures pharmaceutical-grade cannabis extracts in their state-of-the-art labs. These products subsequently sell via Vireo-owned dispensaries to qualifying patients in Minnesota and New York. The Company currently distributes its products via third-party dispensaries in Pennsylvania, Maryland and Ohio.

Vireo Health International collaborates with research organizations to better understand medical cannabis, its applications, and its safety. These partnerships help to reinforce and improve the scientific foundation of the beneficial effects of cannabis and its ability to treat an array of medical conditions.

The Company’s products contain highly-purified, double-distilled, precisely formulated medical marijuana extracts with strain specific terpenes to maximize the entourage effect. Vireo’s extracts and oral solutions include Vireo Red (19.1), Vireo Yellow (6.1), Vireo Green (1.1), Vireo Blue (6.1), and Vireo Indigo (19.1). These numbers represent the THC to CBD ratio.

Recently, Vireo Health announced that its shares have been included in the Horizons US Marijuana Index ETF (HMUS) and the Horizons Emerging Marijuana Growers Index ETF (HMJR). The Horizons US Marijuana Index (HMUS) seeks to track the price movements of a portfolio of North American publicly listed companies with significant business activities in the U.S. marijuana or hemp industries.

The design of the Horizons Emerging Marijuana Growers Index (HMJR) is to provide exposure to the performance of a basket of mainly North American publicly listed small-capitalization companies chiefly involved in the cultivation, production and/or distribution of marijuana.

Last week, Vireo Health of New York announced that patients living in the New York City metro area, Westchester County, and Nassau County now have access to free, same-day marijuana delivery. Launched in April of 2017, Vireo Health's medical marijuana home delivery service has quickly expanded. Since its inception, Vireo has made greater than 25,000 home deliveries to patients. Vireo is now the first company in New York to offer a free same-day delivery option.

Vireo Health International, Inc. (VREOF), closed Wednesday's trading session at $2.19, up 0.004566%, on 28,486 volume with 69 trades. The average volume for the last 3 months is 28,281 and the stock's 52-week low/high is $2.03999996/$5.06264019.

chart

Rezolute, Inc. (RZLT)

Spotlight Growth, Emerging Growth, MarketWatch, Dividend Investor, Market Screener, OTC Markets, Simply Wall St, GuruFocus, Street Insider, Investing Online, The Street, Stockopedia, Morningstar, InvestorsHub, 4-Traders, Barchart, last10k, Stockhouse, YCharts and Wallet Investor reported earlier on Rezolute, Inc. (RZLT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Rezolute, Inc. is a clinical stage biopharmaceutical company headquartered in Louisville, Colorado. It specializes in the development of innovative drug therapies for metabolic and orphan diseases. The Company formerly went by the name AntriaBio, Inc. It changed its corporate name to Rezolute, Inc. in December of 2017. Rezolute’s shares trade on the OTC Markets Group’s OTCQB.

Rezolute is advancing a divers pipeline. This pipeline includes RZ358 (Phase 2). This is an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy. In addition, the pipeline includes AB101 (Phase 1). This is a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management through reducing the therapeutic burden for patients and improving compliance. The Company’s pipeline also includes a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds. One is RZ402 targeting Diabetic Macular Edema (DME). The other is RZ602 targeting Hereditary Angioedema (HAE), an orphan indication. Rezolute and XOMA Corporation have executed a license agreement. The agreement provides Rezolute with the exclusive international rights to develop and commercialize RZ358 (formerly XOMA 358) for Congenital Hyperinsulinism (CHI), an ultra-orphan indication. XOMA is a pioneer in the discovery, development, as well as licensing of therapeutic antibodies. RZ358 is a first-in-class fully human monoclonal antibody. It counteracts the effects of elevated insulin via allosteric modulation of the insulin receptor. This makes it well-suited as a therapy for severe, persistent hypoglycemia caused by hyperinsulinemic conditions such as CHI. Recently, Rezolute announced that it entered into a $25 million preferred stock purchase agreement with two pharmaceutical companies that have elected to make a strategic investment in Rezolute. The investors include Handok, Inc., and Genexine, Inc., two premier publicly traded South Korean-based pharmaceutical companies. These two have a collective market capitalization of greater than $1.7 billion. With this agreement, each preferred share is priced at $5.00 and automatically converts into shares of Rezolute’s common stock at an implied per share price of $0.22. Rezolute’s intention is to use the proceeds from this offering to advance its clinical programs. This includes initiating a Phase 2b clinical study for RZ358 in the U.S. and Europe; completing the required toxicology studies for RZ402 to enable the filing of an IND and initiation of clinical studies; and completing an ongoing Phase 1 study for AB101.

Rezolute, Inc. (RZLT), closed Wednesday's trading session at $0.38, up 15.1515%, on 48,350 volume with 13 trades. The average volume for the last 3 months is 12,200 and the stock's 52-week low/high is $0.090000003/$0.495999991.

chart

FieldPoint Petroleum Corp. (FPPP)

Stock Twits, OTC Markets, Equity Clock, Investing Note, InvestorsHub, Investors Hangout, Real Investment Advice, Market Screener, Wallet Investor, MarketWatch, The Street, and Street Insider reported earlier on FieldPoint Petroleum Corp. (FPPP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

FieldPoint Petroleum Corp. engages in the acquisition, development, and operation of oil and natural gas properties in the U.S. The Company engages in oil and natural gas exploration, production, and acquisition, primarily in Louisiana, New Mexico, Oklahoma, Texas, and Wyoming. FieldPoint Petroleum has its corporate office in Austin, Texas. The Company lists on the OTC Markets’ OTCQB.

Currently, FieldPoint has varying ownership interests in 480 gross producing wells (96 net) in the above-mentioned States. The Company’s strategy centers on expanding its reserve base. This is while increasing production and cash flow through the acquisition of leasehold interests and producing oil and gas wells.

FieldPoint Petroleum has more recently chosen to concentrate on promising areas for oil & gas exploration. These areas include the Lusk Field in Lea County, New Mexico, and the Company’s Ranger Project in the Taylor Serbin Field near Giddings, Texas.

In projects such as these, FieldPoint Petroleum partners with companies that complement internal expertise in evaluating opportunities and in making investment decisions. Regarding producing oil & gas properties, FieldPoint operates 19 wells. Independent contractors operate the other wells per standard industry contracts.

In Wyoming, FieldPoint is active in Converse County and Campbell County. The Company is active in Lea County, Chaves County, and Eddy County in New Mexico. In Texas, FieldPoint is active in Andrews County, Midland County, and Lee & Bastrop Counties. In Louisiana, it is active in Caddo Parrish. In Oklahoma, the Company is active in Grady County and Pontotoc County.

Concerning operated wells, FieldPoint’s portfolio includes mainly low-touch, “pumper and electricity-only” wells in the Devonian, Ellenberger, and Morrow areas of West Texas and New Mexico. Higher maintenance fields are closer to home. These include the Taylor Serbin field near Giddings, Texas. Most of FieldPoint’s production comes from its East Lusk and Serbin Fields.

Recently, FieldPoint Petroleum announced financial results for the third fiscal quarter ended September 30, 2018. Mr. Phillip Roberson, President and Chief Financial Officer, said, "Revenues were down year over year due primarily to the sale of our Apache Bromide production, which occurred in 2017. The Apache Bromide was a high operating cost asset that did not contribute significantly to the bottom line. We did not have a similar sale in 2018, although we are considering that possibility in the future. I am pleased to announce that we have been able to extend our forbearance agreement with Citibank until March 31, 2019, giving us some latitude to evaluate and consider merger, acquisition, and financing opportunities that have been difficult to pursue under a shorter forbearance period."

FieldPoint Petroleum Corp. (FPPP), closed Wednesday's trading session at $0.131, up 274.2857%, on 1,049,000 volume with 371 trades. The average volume for the last 3 months is 5,034 and the stock's 52-week low/high is $0.035/$0.230000004.

chart

Explor Resources, Inc. (EXSFF)

Streetwise Reports, Vantage Wire, Stockhouse, and InvestorsHub reported earlier on Explor Resources, Inc. (EXSFF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Explor Resources, Inc. is a natural resources company headquartered in Rouyn-Noranda, Quebec.  The Company has mineral holdings in Ontario, Quebec, Saskatchewan and New Brunswick. Its Flagship project is the Timmins Porcupine West (TPW) Project situated in the Porcupine mining camp in Ontario. A gold and base metals exploration company,  Explor Resources lists on the OTC Markets Group’s OTCQB.

  The Company is presently concentrating on exploration in the Abitibi Greenstone Belt. This belt is in both provinces of Ontario and Quebec - roughly 33 percent in Ontario and 67 percent in Quebec.  Explor’s total land position in the Abitibi Greenstone Belt is about  25,000 hectares. In addition, Explor owns 6,500 hectares of mining claims in New Brunswick.

   Abitibi Greenstone Belt properties 100 percent-owned by the Company in Ontario include Carnegie, Kidd Township, Eastford Lake, PG-101, Montrose, Golden Harker, Timmins Porcupine West, and Ogden. Abitibi Greenstone Belt properties 100 percent-owned by Explor Resources in Quebec include East Bay, Nelligan, Destor, and Launay. 

Explor Resources has signed a Memorandum of Understanding (MOU) with the Matachewan First Nation of Matachewan, Ontario and the Mattagami First Nation of Gogama, Ontario, concerning the Montrose Property. The MOU will serve as a structure to govern the relationship between Explor Resources and the First Nations in accordance with their intention of further building a relationship characterized by cooperation and mutual respect, in connection with the development of the Montrose Property.

The Montrose property consists of 20 mining claims (217 units) positioned in the Montrose and Midlothian Townships in the Timmins-Porcupine Mining Camp for a total of around 3,472 hectares.

In December 2017, Explor Resources announced the acquisition of two mining claims (3 units) located in Ogden Township, in the Porcupine Mining Division, District of Cochrane, Ontario for a total of 48.56 hectares. The claims are in Ogden Township contiguous and to the east of the Timmins Porcupine West Gold Property.

The claims were acquired because of encouraging results obtained in the Company's past exploration on the property. Explor Resources will pay CDN $2,000 and issue 100,000 common shares to obtain a 100 percent interest in the additional Ogden mining claims. The Optionors have retained a 2 percent NSR (Net Smelter Return) in the property.

Recently, Explor Resources announced the results of the East Bay Gold Property exploration program. The analysis of earlier exploration by Cambior and the results of the previous exploration program completed by Explor Resources confirmed a number of interesting drill targets. The exploration program comprised a Phase III 3000 meter drill program.

The East Bay Gold Property is positioned to the west of the Consolidated Beattie and Donchester Gold Property. It is contiguous to the ground on which the former Clifton Star Resources, Inc. intersected wide width of gold mineralization.

Furthermore, Explor Resources announced recently the acquisition of eight mining claims (64 claim units) located in Hoyle Township, in the Porcupine Mining Division, District of Cochrane, Ontario for a total of 1036.4 hectares. The claims are positioned in Hoyle Township, north of Bell Creek, Owl Creek and Hoyle Pond gold Mines.

The claims were obtained because of results attained by Tahoe Resources and Goldcorp in their exploration programs in Hoyle Township. Explor Resources will pay CDN $1,000 and issue 3,000,000 common shares to obtain a 100 percent interest in the property.

Explor Resources, Inc. (EXSFF), closed Wednesday's trading session at $0.0203, up 53.7879%, on 101,440 volume with 5 trades. The average volume for the last 3 months is 17,158 and the stock's 52-week low/high is $0.006699999/$0.035.

chart

Blow & Drive Interlock Corp. (BDIC)

MarketWatch, YCharts, TradingView, Equities.com, and News to Watch reported on Blow & Drive Interlock Corp. (BDIC),  and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Blow & Drive Interlock Corp. provides automotive and criminal offender monitoring security products. The Company has its state-of-the-art ignition interlock device, the BDI-747. The device is approved and available in eight states for evidentiary and preliminary screening use. In essence, Blow & Drive Interlock is an offender monitoring and police-grade alcohol detection device manufacturing and offender monitoring business.  Blow & Drive Interlock is based in Los Angeles, California. 

  Interlocks are required for use by DUI or DWI (Driving Under The Influence or Driving While Intoxicated) offenders. This is as part of their mandatory court or motor vehicle department program. The Company’s aim  is to have the BDI-747 available to customers across the U.S.

In addition, Blow & Drive Interlock continues to do research and development (R&D) on the next stage of offender monitoring. The Company believes this will be Smartphone enabled monitoring applications, which could reduce or eliminate  the requirement for ankle bracelets or hand-held breathalyzers.  

  The BDI-747 is an ignition interlock device, breath-alcohol testing device about the size of a Smartphone. The ignition interlock device requires the driver to exhale into the device prior to starting the vehicle. The device will prevent the vehicle from starting if the driver's blood-alcohol content exceeds a predetermined set level. 

  The BDI-747 can record BAC levels. It provides 2-way communication, GPS location technology, and image technology. Moreover,  the BDI-747 is wireless.

One of Blow & Drive Interlock’s new products is its Home Alcohol Monitoring Device. This handheld device has a camera and GPS/WIFI & live streaming. It enables those in Judicial and Probation departments to monitor offenders who are required to stay sober from alcohol while on probation.

The Company also has its 4G LTE Live-Streaming Video Body Worn Camera for Law Enforcement. With the 4G LTE Live-Streaming Video Body Worn Camera, Law Enforcement Personnel on the scene can transmit a live feed from their body cameras to headquarters. This allows police decision makers’ access to real time information regarding what each officer is seeing.

The body camera weighs roughly 210g. It provides up to 32 GB of memory and 5-megapixel recording.

Recently, Blow & Drive Interlock introduced BADGECAM. This is a body worn camera akin to the models law enforcement officers use but to protect anyone at anytime. The BADGECAM can be heavily incorporated by Human Resources (HR) departments, security personnel, counter staff, or any other jobs that come with a potential confrontation.

The intention of BADGECAM is to become a vital preventative measure against workplace violence, discrimination, or personal/sexual harassment. With BADGECAM, one can immediately begin recording up to 6 hours of high quality video and audio with a single pull.

The design of BADGECAM is to be affixed to any article of clothing. Blow & Drive Interlock plans to launch the BADGECAM between Q2 and Q3 of 2018.

Blow & Drive Interlock Corp. (BDIC), closed Wednesday's trading session at $0.097, up 73.2143%, on 400 volume with 2 trades. The average volume for the last 3 months is 1,290 and the stock's 52-week low/high is $0.050099998/$0.200000002.

chart

Boston Therapeutics, Inc. (BTHE)

MissionIR,  Tiny Gems, SmallCapVoice, PennyStocks24,   FeedBlitz, Wall Street Mover,  RedChip, TaglichBrothers,  Stock News Now, TopPennyStockMovers, and Information Solutions Group  reported  earlier  on Boston Therapeutics, Inc. (BTHE), and  today we are reporting on  the Company, here at the QualityStocks Daily Newsletter. 

Boston Therapeutics, Inc. is a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases. The Company’s product pipeline  centers  on developing and commercializing therapeutic molecules  that  address diabetes and inflammatory diseases. OTCQB-listed,  Boston Therapeutics is based in Lawrence, Massachusetts.

The Company’s  product pipeline includes BTI-320. This is a  non-systemic, non-toxic,  chewable complex carbohydrate-based compound. The design of it is to lessen post-meal glucose elevation. BTI-320 is a proprietary polysaccharide. 

  BTI-320 works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes, which break down complex carbohydrates into simple sugars, reducing  the availability of glucose for absorption into the bloodstream. 

  Boston Therapeutics  entered a  clinical trial agreement with Joslin Diabetes Center to be the lead clinic  in a Phase II study of BTI-320. In addition,  the Company’s  product pipeline  includes IPOXYN™. This is an injectable anti-necrosis drug. The design of it at first is to treat lower limb ischemia associated with diabetes.  

  Boston Therapeutics’  product pipeline also  includes OXYFEX™. This product can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events. OXYFEX™ is  the Company’s  veterinary facsimile to IPOXYN™.

Furthermore, Boston Therapeutics  developed and markets SUGARDOWN®. This is a non-systemic,  complex carbohydrate-based dietary food supplement. The design of SUGARDOWN® is to support healthy blood glucose.

SUGARDOWN®, in its present formulation, is a natural sugar blocker dietary supplement product made completely from a non-digestible sugar molecule, which can help people maintain healthier weight levels. It is the first chewable tablet of its kind. 

  In 2015, Boston Therapeutics announced that its affiliate, Advance Pharmaceutical Company Limited (APC), began the  SUGARDOWN®  clinical trial in Hong Kong. Advance is evaluating the effect of  SUGARDOWN®  on Post-Prandial Hyperglycemia in Chinese subjects with Pre-Diabetes.  The lead clinical site is the Department of Medicine, The Chinese University of Hong Kong  (CUHK), Prince of Wales Hospital. 

  In April 2017, Boston Therapeutics and  Advance Pharmaceutical announced the fully funded new trial plans to support the safety and efficacy of BTI-320, starting with a randomized, placebo-controlled, double-blinded, multi-center, global study on type 2 diabetic (T2D) patients.

Recently, Boston Therapeutics announced that effective sugar reduction with the investigative BTI-320 formulation necessitates only one tablet. Findings were confirmed by the most recent proof-of-concept study conducted in high-risk Chinese subjects with pre-diabetes. A formulation, in the form of a dietary supplement, is currently available as SUGARDOWN®, SUGARBLOCK and SUGARBALANCE in the Unites States and Asia.

Moreover, in December, Boston Therapeutics announced that it expanded its partnership with Advance Pharmaceutical Company Limited (APC) to distribute in Korea. Following the extension of the licensing and distribution agreement with APC, a registered formulation, marketed as a food supplement under the name SUGARBALANCE is now available in Korea. This significant shipment marks a start to the sales of SUGARBALANCE in the territory.

Boston Therapeutics, Inc. (BTHE), closed Wednesday's trading session at $0.018, up 43.4034%, on 243,385 volume with 10 trades. The average volume for the last 3 months is 33,601 and the stock's 52-week low/high is $0.0102/$0.074900001.

chart

Spindle, Inc. (SPDL)

TopPennyStockMovers and SmallCapVoice reported previously on Spindle, Inc. (SPDL), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Spindle, Inc. (dba CATALYST Commerce Solutions) is an emerging provider of integrated marketing and commerce solutions focused on the Small and Medium-sized Business (SMB) market. The Company is an innovator of merchant and consumer-facing commerce solutions. It is concentrating on pioneering new ways for businesses to quickly integrate mission critical business services, payment acceptance, and mobile marketing services. This is while empowering location-based merchant discovery, fulfillment, and frictionless consumer engagement. OTCQB-listed, Spindle is headquartered in Mesa, Arizona.

The CATALYST Marketing System components and CATALYST IP were included in the asset acquisition from Catalyst Business Development, Inc. that Spindle completed in 2015. Catalyst Business Development is a Scottsdale, Arizona-based provider of payment gateway services, sales, and software solutions.

Spindle’s commitment is to provide innovative solutions that surpass traditional boundaries, and allow clients, partners, merchants, and consumers to take full advantage of the fast-developing mobile economy. Spindle is focusing on payment processing services and integrating value-added capabilities that enhance merchant revenue and increase consumer loyalty, experience, and retention.

The Company integrates acceptance channels. Spindle is also pushing the boundaries through adding big data collection, analytics, marketing, loyalty and points programs and integration with other domains (including security systems and business automation products). Regarding Point-Of-Sale (POS) & MPOS, Spindle has a POS solution built around the power of the cloud. This is for restaurants and retail to mobile vendors and event organizers.

Spindle acquired Yowza!! - a provider of mobile couponing technology. This technology is integrated with Spindle's platform. Spindle signed distribution agreements with a broad array of channel partners. Via these relationships, it can provide wide-ranging mobile commerce services through many channels. These channels include wireless providers, vending services operators, and technology solutions providers.

Spindle has finalized an agreement to acquire specific digital marketing software assets from CoverCake, Inc., specifically CoverCake's intelligent algorithms for data mining and consumer engagement. CoverCake's software is envisioned to enhance the sophistication and proprietary strengths of Spindle's CATALYST Platform. CoverCake's software capabilities include intelligent content aggregation; data mining on different social media data feed platforms, and a strong Content Management System (CMS) backend.

Spindle has executed two strategic agreements with Concourse Team Express. With this strategic relationship, Team Express will use the CATALYST Team Sports Platform to offer teams the ability to manage their rosters, collect fees, integrate social media, team scheduling, statistics, location directions, and more. CATALYST Team Sports will be adding the Team Express custom teamwear and team store solutions to the platform. Team Express is a top multi-channel internet retailer.

Recently, Spindle announced the launch of the CATALYST Marketing System. The platform has been further enhanced through integrating the Company's customized CATALYST software with solution providers, the CATALYST Gateway, and its recently acquired software from CoverCake. The CATALYST Marketing System (CMS) enables SMBs the ability to manage their business from one central hub.

Spindle, Inc. (SPDL), closed Wednesday's trading session at $0.0002, up 100.00%, on 2,737,851 volume with 5 trades. The average volume for the last 3 months is 4,552,329 and the stock's 52-week low/high is $0.000099999/$0.084799997.

chart

Zinc One Resources, Inc. (ZZZOF)

NetworkNewsWire, 4-Traders, MarketWatch, YCharts, InvestorX, InvestorsHub, Market Screener, Wall Street Profiler, Streetwise Reports, InvestorIntel, Stock of the Week, Epic Stock Picks, All Penny Stocks, Stockhouse, Dividend Investor, Insider Financial, Marketwired, Investing News, Barchart, StockInvest, Wallet Investor, Investor Ideas, and Investors Hangout reported previously on Zinc One Resources, Inc. (ZZZOF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Zinc One Resources, Inc. concentrates on the acquisition, exploration and development of prospective and advanced zinc projects in mining-friendly jurisdictions. Its key assets are the past producing Bongará Zinc Mine Project and the Charlotte-Bongará Zinc Project in Peru. The Company formerly went by the name Rockridge Capital Corp. It changed its corporate name to Zinc One Resources, Inc. in January 2017. Zinc One Resources is based in Vancouver, British Columbia.

The Company acquired Forrester Metals, Inc. in June of 2017. As a result, it acquired the Bongará Mine and Charlotte-Bongará Projects. Both host high-grade, nonsulphide zinc mineralization at or near the surface. At the Bongará Zinc Mine the mineralization is concentrated along and proximal to a NW – trending anticlinal axis over approximately 2.5 kilometers.

The Bongará Zinc Mine was mined in 2007 and 2008 by a previous owner by open-pit methods, dried at the site, and then shipped 540 kilometers westward to the coast where it was processed via a Waelz kiln. This is a processing technology usually applied to flue dust from steel mills to recover zinc. In August 2008, the mine was closed down mainly due to a drop in the price of zinc at that time.

The exploration upside at Charlotte-Bongará includes greater than 8,000 meters of drilling. This includes results of 29.5% Zn across 15.5 meters, 26.1% Zn across 12.5 meters, and 29.7% Zn across 11.5 meters.

Recently, Zinc One Resources announced the first National Instrument 43-101 (NI 43-101) Mineral Resource estimate for its Bongará Zinc Mine project in north-central Peru. Watts Griffis and McOuat Limited (WGM) prepared the estimate for the Company. A supporting NI 43-101 technical report will be available under Zinc One Resources’ profile on SEDAR at www.sedar.com and on the Company's website at www.zincone.com within 45 days of this release (dated February 5, 2019).

Zinc One Resources also recently announced the results of voting at the Company’s Annual General Meeting (AGM) of shareholders that took place on March 13, 2019, in Vancouver, British Columbia. Shareholders at the AGM approved all matters. This included the appointment of the four incumbent directors - Dr. William C. Williams, Mr. Barry Girling, Mr. Greg Crowe, and Mr. Gunther Roehlig, for the following year, the re-appointment of Charlton & Co. LLP as auditors of Zinc One Resources, and the renewal of the Company's 10 percent rolling stock option plan.

Zinc One Resources, Inc. (ZZZOF), closed Wednesday's trading session at $0.024, up 129.6651%, on 61,579 volume with 14 trades. The average volume for the last 3 months is 19,275 and the stock's 52-week low/high is $0.009999999/$0.158999994.

chart

The QualityStocks Company Corner

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Cannabis-infused products manufacturer Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) is creating edibles to support a health and active lifestyle for both new and veteran consumers. Drawing from more than 40 years of experience in food manufacturing, the company makes edibles from scratch using only the highest-quality extracts and kosher ingredients to create a consistent and delicious cannabis experience. To do this well requires foresight and the collaboration of a well-orchestrated team of experts across multiple fields. The PLUS team includes Michelin-star chefs, Ivy League chemists, food manufacturing experts, engineers, machinists, visionaries, creatives and strategists. Also today, the company was highlighted in a publication from Financialnewsmedia.com, examining how almost everyone has heard the term “CBD”, even people who have never smoked recreational marijuana or have received a medical marijuana prescription… or even those who are not actively following the U.S. stock markets… CBD is everywhere!

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Wednesday's trading session at $2.752, up 3.4548%, on 27,331 volume with 69 trades. The average volume for the last 3 months is 60,169 and the stock's 52-week low/high is $2.51999998/$6.00810003.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) announced today that Ash Rajendra has joined the company as Chief Information Officer ("CIO") where he will focus on ensuring Supreme Cannabis is well prepared to execute on its next phase of growth. The Company also announced the addition of a new VP, Talent, Valerie Rother to steward the Company's human capital and talent development program.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Wednesday's trading session at $1.07, up 2.3238%, on 152,286 volume with 235 trades. The average volume for the last 3 months is 318,926 and the stock's 52-week low/high is $0.850000023/$2.03999996.

Recent News

chart

TransCanna Holdings Inc. (CSE: TCAN) (FRA: TH8)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

TransCanna Holdings Inc. (CSE: TCAN) (FRA: TH8) was featured today in the 420 with CNW by CannabisNewsWire. The U.S. Food and Drug Administration (FDA) started receiving comments on CBD regulation from the public and other stakeholders in April and the comments period came to an end early last week. The agency had initially planned to close the comments period on July 2 but the overwhelming public interest in the matter led the FDA to extent that deadline to July 16. By the close of the comments period, more than 4,400 submissions had been filed by individuals and organization.

TransCanna Holdings Inc. (CSE: TCAN) (FRA: TH8) brings together a rapidly growing portfolio of cannabis and hemp-related brands and services, with a closed-loop ecosystem approach rooted squarely in the company’s ownership of a 196,000-square-foot, vertically integrated facility in California. The company has developed a two-year, four-phase plan aimed at developing proprietary brands and creating a self-contained ecosystem that ensures reliability, consistency, quality and scale.

Ecosystem

TransCanna’s cannabis facility in Modesto, California, is strategically located less than a three-hour drive from the majority of all major cities in the state. The tri-level building provides internal control of everything needed for the seed-to-sale cycle, from growing and manufacturing to extraction, bottling, transportation and distribution. The facility, which recently went through an US$8 million renovation, is upgraded with a premium quality HVAC system and highly insulated roof to help reduce power costs, which already are some of the lowest in California.

The company has set 2020 goal for implementation of its full-service software platform, 420 Global, which will interact with every aspect of production flow, business development and the sales process.

Growing Portfolio

Acquisitions slated to be completed in June include Goodfellas Group LLC, a full-service advertising and marketing agency for the U.S. cannabis and hemp industries. Under the deal, TransCanna will also be acquiring Daily Cannabis Goods, a pre-rolled brand with nominal start-up costs and superior SKU velocity with cannabis products available at more than 30 dispensaries throughout California.

On Deck

The company has moved to acquire organic hemp-infused CBD coconut oil Biovelle (www.Biovelle.com). Biovelle is non-GMO, vegan and gluten free, with coconut sourced from plantations in the Philippines and American grown hemp from farms in Colorado.

TransCanna has also moved to further secure a growing foothold in cannabis edibles via a non-binding letter of intent with Persuasion Brewing Co., located near the company’s flagship facility in Modesto. The goal is to establish a Persuasion Brewing division at the main facility, which will produce a variety of different CBD infusion non-alcoholic beers.

Similarly, the company has recently executed a non-binding LOI with SolDaze (Tres Ojos Naturals, LLC) to gobble up the branding asset package of this California manufacturer of cannabis-infused fruit snacks (www.soldazesnacks.com).

Management

TransCanna’s management team consists of seasoned agriculture and consumer goods-oriented veterans.

Director, CEO and Chairman James Pakulis has 30 years of experience working with public and private entrepreneurial companies in a variety of emerging sectors. He has been on the front lines of the California cannabis industry for nearly a decade. He was CEO and chairman in 2010 of General Cannabis, Inc., which wholly owned the popular Weedmaps brand. Pakulis oversaw the growth of General Cannabis from pre-embryonic stages to over $16 million in revenue in less than two years, reaching a market cap of approximately $480 million.

Director and President Arni Johannson brings over 30 years of investing experience in the Canadian capital markets. He has built and or funded over 50 startups from around the world. He is president of Canadian Nexus Ventures and has been instrumental in providing guidance to pre- and post IPO companies, as well as guidance and oversight for corporate governance.

Stephen Giblin, board director, is an accomplished leader in the global hospitality, technology and real estate industries with a demonstrated track record of value creation. Juan Pablo Flores, independent director, is an attorney with more than 25 years of legal experience with a strong background in municipal, government, real estate, corporate and general civil law litigation.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

TransCanna Holdings Inc. (CSE: TCAN), closed Wednesday's trading session at $1.42, up 4.41%, on 74,519 volume. The average volume for the last 3 months is 165,804 and the stock's 52-week low/high is $1.18/$7.78999996.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), an innovator in drug delivery platforms, today announce a multi-faceted expansion of their relationship with Hill Street Beverage Company Inc., (TSX.V: BEER; “Hill Street”). Hill Street and Lexaria have entered into a Joint Manufacturing Partnership (“JMP”) valid for 10 years to produce jointly created DehydraTECHTM commercial products under a new brand to be announced, including processed THC cannabis and/or CBD hemp powder for new consumer products including among other categories; tablets, capsules, or packets for sale in Canada and for export where permitted. The JMP will also produce similar powders as a bulk ingredient for manufacturing processes for sale to other licensed producers seeking to use Lexaria’s advanced infusion technologies to create their own wide variety of products for sale within Canada.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Wednesday's trading session at $0.77, up 4.7619%, on 47,813 volume with 52 trades. The average volume for the last 3 months is 82,968 and the stock's 52-week low/high is $0.730000019/$2.24.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech Inc. (OTCQB: ETST) was named in an InvestorPlace article by Mark Putrino as one of ‘7 Marijuana Penny Stocks I May Buy’, in large part because of the extensive business and industry experience of ETST’s executive team and advisory board (http://nnw.fm/2FmVE).

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed Wednesday's trading session at $0.75, up 6.8483%, on 14,495 volume with 13 trades. The average volume for the last 3 months is 57,614 and the stock's 52-week low/high is $0.300999999/$2.45000004.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) was featured today in the 420 with CNW by CannabisNewsWire. The U.S. Food and Drug Administration (FDA) started receiving comments on CBD regulation from the public and other stakeholders in April and the comments period came to an end early last week. Several health associations and medical professionals in particular submitted comments to the effect that the agency should regulate CBD as a health supplement as long as strict labeling and quality standards are set for manufacturers.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed Wednesday's trading session at $0.364818, up 0.878774%, on 255,037 volume with 75 trades. The average volume for the last 3 months is 216,866 and the stock's 52-week low/high is $0.330000013/$1.52999997.

Recent News

chart

MustGrow Biologics Corp. (CSE: MGRO)

The QualityStocks Daily Newsletter would like to spotlight MustGrow Biologics Corp..

MustGrow Biologics (CSE: MGRO), an agricultural biotech company developing and commercializing a portfolio of natural biopesticides and biofertilizers, this morning announced that it will present its previous research findings in collaboration with Virginia Tech’s Southern Piedmont Agricultural Research and Extension Center in Blackstone, Virginia. To view the full press release, visit: http://nnw.fm/Zr0nc.

MustGrow Biologics (CSE: MGRO) is an agricultural biotech company focused on developing and commercializing its patented technology that is a natural biopesticide and biofertilizer for use as a fertilizer, nematicide, pesticide and fungicide. MustGrow’s novel and proprietary solutions utilize organic components refined from mustard seed to provide high quality, organic pest control to growers facing challenges associated with soil-borne diseases and pests such as nematodes. The company’s technology provides an all-natural, effective, safe and easy-to-use solution for farmers seeking to raise healthy crops without the use of pesticides.

Nematodes, or microscopic worms, are the most numerous multicellular animals on earth. A handful of soil will contain thousands of nematodes, many of which are parasites of insects, plants or animals. Most plant-parasitic nematodes feed on the roots of plants, damaging the root system and reducing the plant’s ability to absorb water and nutrients (http://nnw.fm/Qkz21). For the past 50 years, nematodes have been controlled using chemical nematicides, but the Environmental Protection Agency now restricts or bans many of the chemical?formulations.

MustGrow’s technologies provide nematode control that is equal and often superior to synthetic alternatives, resulting in elevated yields and increased returns for the grower. The global economic impact of soil-borne nematodes is estimated at nearly $100 billion in lost crops per year. The American Phytopathological Society (http://nnw.fm/3HGuT), an international nonprofit scientific organization dedicated to the study and control of plant diseases, estimates that plant-pathogenic nematodes are responsible for 14 percent of crop losses worldwide.

MustGrow’s technology refines mustard seeds to concentrate the plant’s natural organic compounds that form Allyl isothiocyanate (“AITC”), which serves the plant as a natural defense system against pests and diseases. As a result, MustGrow’s novel product offers first-class performance, is 100 percent natural, and its fertilizer product is listed for organic use by the Organic Materials Review Institute (“OMRI”) under specifications set by the USDA’s National Organic Program.

MustGrow’s initial technology was a granular pre-plant soil biofumigant and biofertilizer containing the active ingredient AITC, a proven nematicide, fungicide and fertilizer. The company has completed 110 independent third-party field trials on fruit and vegetable crops. As a biofertilizer, MustGrow’s product is registered with Health Canada and the EPA in all U.S. states as OMRI-certified. It is also registered for use as a biopesticide by the EPA in key fruit and vegetable growing U.S. states (except California) and with Health Canada. MustGrow is finalizing a new liquid delivery platform with increased concentration of the same active ingredient (AITC) that can be applied through drip lines to meet the demands of today’s growers.

Results of tests completed to date show that MustGrow continues to provide innovative solutions with broad based applications within agriculture. Validated field trial results include:

  • 100 percent control of root-knot nematodes in strawberry crops as compared to methyl bromide
  • 55 percent tomato crop yield increase
  • 95 percent control of Pythium root rot in lettuce fields
  • 70 percent reduction in Verticillium root severity in cucumbers
  • Market Opportunity

Market Opportunity??

MustGrow is also testing the potential application of its technology to the cannabis industry, which is projected to grow to nearly $22 billion in the U.S. by 2020. While there are no uniform guidelines for pesticide use in the cannabis industry, state-by-state regulations in the U.S. do exist which has led to instances of pesticide-tainted cannabis showing up in tested products, leading to recalls and threats of lawsuits. Health Canada recently published regulations for mandatory testing for pesticides in cannabis that are now in effect for all growers.?MustGrow’s?potential application for cannabis production shows that when its product is used as a pre-plant/pot soil treatment, it may significantly help control many soil-borne diseases, pathogens and pests, including nematodes, fusarium, rhizoctonia, and botrytis (gray mold) that affect the cannabis plant. Cannabis consumers are increasingly demanding organic products free from chemicals and have shown they are willing to pay a premium for high-quality organic cannabis. MustGrow is currently running cannabis soil trials and is seeking Health Canada approval for use of its product on cannabis.?

Global crop protection is a multibillion-dollar market that is expected to surge over the next five years. Sales of nematicides are set to grow by 33 percent to $1.43 billion by 2022, while biopesticides are projected to leap by 94 percent to an estimated?$9.5 billion by 2022. MustGrow is targeting the global nematicide industry with products that include an innovative pre-plant soil treatment. Solutions for the global biopesticide industry include seed treatment technologies, fungicides and nematicides.??

MustGrow’s groundbreaking technologies use novel plant compounds to provide superior crop protection naturally.

Management Team

President and CEO Corey Giasson is an entrepreneur with more than 20 years in the agriculture, potash, oil and gas, mining and real estate industries.? Mr. Giasson co-founded Rallyemont Energy Inc., a heavy oil company that successfully identified 140 million barrels of recoverable heavy oil, that was sold in 2013 to Husky Energy. He holds an MBA and bachelor’s degree in agricultural economics from the University of Saskatchewan.

Chairman Brad Munro has 20-plus years as a vice president/investments, with a national venture capital firm where he sourced, invested and managed the activity of over 30 companies and invested $150 million. He has served as a director of over 20 public companies and a greater number of private enterprises. Munro is currently director of Secure Energy Services.

COO Colin Betsky is the previous vice president/BioAg at Novozymes, where he was responsible for the company’s BioAg business worldwide. He holds a bachelor’s degree in agriculture from the University of Saskatchewan and has more than 20 years of experience in agricultural chemicals and biologics.

Director Tom Flow is the founder and current president of The Flowr Corporation (TSX.V: FLWR) and Licensed Producer of cannabis in Canada. He founded and built MedReleaf, Canada’s most profitable Licensed Producer which was later acquired by Aurora Cannabis?(TSX: ACB) (NYSE: ACB) for $3.2 billion. Flow is widely recognized for his leadership and expertise in building and operating cannabis cultivation facilities.

Director Matt Kowalski has a tremendous amount of experience in the fruit and vegetable and biologics industries. Under his leadership at Natural Industries, a business focused on biological pest control, the company was awarded five EPA registrations: three biofungicides, a bionematicide, and a bioinsecticide. In November 2012, Kowalski led the strategic sale of Natural Industries to Novozymes BioAg. He is the principal owner of Stronghold Keep Inc., an investment corporation.

CFO Todd Lahti has extensive experience evaluating and managing start-up companies in the biotechnology, agricultural and oil and gas sectors, working directly on financing transactions, mergers and acquisitions, corporate strategy, business development, technology transfer and operations set up. He is a Chartered Financial Analyst and a Chartered Professional Accountant.

MustGrow Biologics Corp. (CSE: MGRO), closed Wednesday's trading session at $0.35, up 6.06%, on 73,000 volume. The average volume for the last 3 months is 145,871 and the stock's 52-week low/high is $0.25/$0.41.

Recent News

chart

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF)

The QualityStocks Daily Newsletter would like to spotlight Siyata Mobile Inc. (SYATF).

Siyata Mobile Inc. (TSX-V:SIM / OTCQX:SYATF) is pleased to announce the commercial launch of their latest enterprise Push-to-Talk over Cellular (PoC) offering, the Uniden® UV350 Desktop Dispatch Unit (DDU). The DDU is now available through cellular carriers and distributors in the United States, Canada and Israel.

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) is a leading global developer and provider of Push-to-Talk Over Cellular ("PTT/PoC") systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world's first 3G connected vehicle device as well as the world's first 4G/LTE vehicle mounted smartphone for First Responders and commercial fleets and vehicles.

Siyata is headquartered in Montréal, Québec, Canada.

Product Portfolio

Siyata's suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company's flagship product, the Uniden UV350, is the world's first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada's largest LTE network and PTT community. Expanding its availability, Siyata is completing network approval with two North American Tier 1 operators to launch the UV350 in the U.S. in 2019.

Management Team

CEO and Chairman Marc Seelenfreund is the founder of Siyata. He is also the founder of Siyata's parent company, Accel Telecom, an Israel-based company that specializes in importing and distributing innovative cellular and IP devices to fixed line operators and mobile providers within Israel. Prior to establishing Accel, Seelenfreund was a vice president at Sunrise Corporation in New York where he focused on financing publicly traded technology companies. Seelenfreund has a law degree from Bar Ilan University, is a board member at Israel's leading private university, and has served as an officer in the Israel Defense Forces.

Glenn Kennedy, vice president of sales, has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Kennedy managed sales nationally for Motorola Canada, HTC Communications Canada, and Sonim Technologies. He holds a bachelor's degree in honors business administration from the Richard Ivey School of Business at the University of Western Ontario.

CFO Gerald Bernstein, a professional chartered accountant, has spent 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. He holds a bachelor's degree of commerce as well as a graduate diploma in public accountancy from McGill University. Bernstein has been a member of the Canadian Institute of Chartered Accountants since 1987.

Gidi Bracha, Vice President of Technology, has served in this position since 2011 and spearheaded the development of both the Truckfone, Voyager and UV350. Bracha served in various key positions at Cellcom, Israel's leading cellular provider, including head of car mobility products and director of type approvals. Bracha served as an engineer technician in the Anti-Aircraft division of the Air Force in the Israel Defense Forces and holds a bachelor's degree in engineering and business management from the University of Derby.

Siyata Mobile Inc. (SYATF), closed Wednesday's trading session at $0.3756, even for the day, on 7,000 volume. The average volume for the last 3 months is 61,854 and the stock's 52-week low/high is $0.288599997/$0.446249991.

Recent News

chart

VPR Brands, LP (VPRB)

The QualityStocks Daily Newsletter would like to spotlight VPR Brands, LP (VPRB).

VPR Brands, LP (OTC: VPRB), a market leader in vaporizer technology and design for Cannabis extracts as well as CBD, is proud to announce the pre-market release of the new HoneyStick Brand BeeBox Pro. The days of carrying 2 vapes are over with the launch of the HoneyStick Beebox Pro digital mod battery. This revolutionary Unit allows you to vape your nicotine pods and your 510 thread prefilled cartridges from the same awesome powerplant. Not only does it solve this problem but it takes the solution to "new heights" or next level by giving you better quality and a better vape experience all around. Also today, NetworkNewsWire released a report on the company detailing how VPRB is making a name for itself in the vaping market through product development and partnerships with top international brands. VPRB is focused on offering high-performance, high-quality products that bring value to partners, consumers and investors.

Florida-based VPR Brands, LP (VPRB) is an innovative technology holding company whose assets include patented atomization-related products and technology. VPR Brands' current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate their products within the vaping industry.

VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. The company's current product portfolio is comprised of the following:

  • GoldLine combines premium ingredients and extracts coupled with the newest in technology to achieve the ultimate selection of cannabidiol (CBD) and hemp-based products available anywhere. The product range is designed for a wide variety of consumers and features edibles such as gummies and pure honey stix, tinctures, pre-rolled flower, vapable products and creams. For more information please visit?www.cbdgoldline.com.
  • HoneyStick is a lifestyle brand that combines the features of high tech, high performance, dependability and affordability when it comes to upper tier vaporizers. HoneyStick was first to market in creating a Sub Ohm vaporizer to the latest Ripper and Plasma GQ. The HoneyStick team works with a vast network of growers, extractors and industry figures to bring the needs of patients and recreational users to life. HoneyStick is sold online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about HoneyStick, visit?www.vapehoneystick.com.
  • Helium brings the vaping experience to a new level with intense flavors that are steeped to perfection and chilled at 20 degrees below room temperature. Helium's chillers are scientifically proven to preserve flavor, freshness and aroma. Helium is in a 50ml durable and squeezable bottle with drip tip that is functional from the start, engineered to deliver 77 percent VG.
  • Vaporin delivers Sub Ohm series starter kits. Vaporin also provides an eye-catching display case with multi-packs of selected starter kits, coils and premium e-liquids for retail and dispensary operations.
  • Vaporx offers the most current, highest quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech, Samsung. Vaporx acts as an extension to a client's purchasing department, providing the option to schedule regular product mix refresh for maximum sales.
  • GoldLine Hemp products are developed specifically for the convenience store market segment. GoldLine Hemp-only products are created without CBD, providing an alternative product line for consumers who are not ready to experience CBD products but still want to take advantage of this rapidly expanding class of products. GoldLine Hemp-only edible Hemp Gummies debuted at the National Association of Convenience Stores (NACS) Expo in Las Vegas in October 2018 and are now being distributed nationwide. The U.S. convenience store industry, with more than 154, 000 stores nationwide, serves 160 million customers daily and has sales that are 10.8% of the total U.S. retail and food service sales. Visit?www.goldlinehemp.com?for more information about GoldLine Hemp-only products.
  • Vapor Store Direct in Fort Lauderdale, Florida, is one of the largest vaporizer and e-liquid wholesalers in the United States. Vapor Store Direct stocks internationally elite brands, vaporizers, tanks/atomizers, coils, e-liquid, e-cigarettes, batteries, glass and accessories.

Management Team

CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, Frija became the president and chief executive officer of Vapor Corp., one of the first U.S. importers and publicly traded electronic cigarette companies. In 2016, Frija purchased the brands and wholesale business assets from Vapor Corp., which is now owned by VPR Brands. Under his leadership, VPR Brands is pivoting toward cannabis products which is increasing sales and profit margins.

Dan Hoff, chief operating officer, has worked in the vaporizer and e-cigarette industry, serving in various positions at Vapor Corp., including overseeing the financial management, accounting functions, supply chain management, product design and development, and key vendor relations. He has played a pivotal role in building and expanding the cannabis-based products division at VPR Brands, which includes a turnkey OEM vapor solutions program available to farmers, cultivators and extractors. Hoff received his bachelor's degree from the University of Miami School of Business.

VPR Brands, LP (VPRB), closed Wednesday's trading session at $0.0492, even for the day, on 9,946 volume with 6 trades. The average volume for the last 3 months is 62,130 and the stock's 52-week low/high is $0.026/$0.119999997.

Recent News

chart

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) was featured today in a publication from Financialnewsmedia.com, examining how, seemingly overnight, CBD is appearing everywhere from beauty product lines to burger joints. As it turns out, there’s legitimate reasoning behind “today’s” latest hype. The recent rise in use and popularity can be primarily attributed to the onset of cannabis legalization across the United States, and most recently, the passage of the 2018 Farm Bill… According to the newest service offered by BDS Analytics, CBD Market Monitor, U.S. sales of cannabis- and hemp-derived CBD products are expected to surge to $20 billion by 2024.

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed Wednesday's trading session at $5.94, off by 2.1417% (up 2.69% after hours), on 1,175,982 volume with 3,990 trades. The average volume for the last 3 months is 1,113,270 and the stock's 52-week low/high is $2.97000002/$8.43999958.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced its entry into a contract services agreement with a multi-billion biotherapeutics company to enhance the manufacturing process of one of their candidate protein drugs. To view the full press release, visit: http://nnw.fm/RLA6d.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Wednesday's trading session at $3.05, off by 1.6129%, on 12,075 volume with 33 trades. The average volume for the last 3 months is 8,747 and the stock's 52-week low/high is $1.51999998/$4.0999999.

Recent News

chart

IONIC Brands Corp. (CSE: IONC) (OTC: IONKF)

The QualityStocks Daily Newsletter would like to spotlight IONIC Brands Corp. (OTC: IONKF).

IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) is pleased to announce that it has completed the acquisition of Natural Extractions, Inc. d/b/a Zoots Premium Cannabis Infused Edibles (“Zoots”), based in Washington, USA, as previously announced on April 23, 2019.

IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) is a national cannabis holding company building a multistate portfolio of award-winning premium and luxury brands in the cannabis space. Established in 2015, IONIC Brands has demonstrated its ability to expand and operate multiple cannabis concentrate consumer brands in leading markets across the western United States, with current operations in Washington, Oregon, California and Nevada. The company continues to strategically expand nationwide to remain a leader of the highest-value segments in the cannabis market.

With a focus on quality, responsibility and respectability, IONIC’s product lines are pioneering the changing landscape of cannabis consumption. The company’s refinement practices are a result of a passionate commitment to craft the finest, small-batch cannabis oils and cannabis concentrates in the world – without glycols, glycerins or additives.

IONIC’s Certified Clean program verifies that every product leaving the company’s facilities meets or exceeds state mandates on pesticide testing. The testing is conducted by individually testing every batch which ensures and enhances trust and transparency. IONIC recently paired its Certified Clean program with Lucid Green Inc. and its revolutionary technology platform designed to provide vital safety information. Lucid Green’s technology provides a direct-to-consumer data platform, providing instant access to a library of product specific insights by simply scanning the package’s QR code with a smartphone camera.

Elite Brand Portfolio/Acquisitions

  • IONIC, the company’s flagship recreational branded product, is a stylish and sophisticated premium vape pen line that has earned customer loyalty and a reputation as a consistent Top 10 vape brand in Washington state. IONIC’s immediate product line expansion plans include THC/CBD mixes, low-dose products, high-end edibles, CASK oil and device innovation.
  • WW Agriculture cultivates cannabis outdoors on a 140-acre eastern Washington State farm capable of producing up to 100,000 pounds of cannabis for less than $0.10/gram.
  • ZOOTS, a Washington-based edibles company, utilizes patent-protected ultra-clean CO2 extraction hardware to create proprietary formulations of refined cannabis oils and distillates. Through MedMen dispensaries, Zoots Edibles are currently available in Washington and Colorado and will soon be on shelves at dispensaries in Massachusetts, New York and Pennsylvania.
  • Vuber Technologies hardware produces the best vaporization experience on the market.
  • Vegas M Stick vaporizer pens are distributed to stores in Washington State with plans to expand to Oregon and Nevada.
  • Vegas Valley Growers is a revenue-generating, vertically integrated operation in Las Vegas, Nevada, with a full complement of production, manufacturing and distribution licenses.

IONIC has also acquired two U.S. patents issued to Canna Café that are related to cannabinoid (CBD) infused coffee and CBD-infused coffee in a Keurig ® K-Cup ® Pod. An international patent is in process for cannabis-infused teas.

Experienced Management Team

IONIC Brands is led by an innovative product team, powerful sales organization and a world-class marketing group.

Chairman & CEO John Gorst has built and sold four different technology companies with market valuations in excess of $600 million. Gorst has been at the forefront of IONIC’s expansion and development into Washington state’s leading vaporizer brand.

Andrew Schell, President, Vice-Chairman & Co-Founder, has built several successful companies. Schell has an engineering background rounded in operations, strategy and corporate law, and most recently was CEO of a U.S. Department of Defense company specializing in military operations.

Christian Struzan, Chief Marketing Officer & Co-Founder, has over 30 years of experience in marketing and branding in the entertainment and consumer goods industries. Struzan founded an advertising agency which developed and executed marketing campaigns for feature films such as the Star Wars franchise, Fight Club, and the television series American Idol. He has also worked on global brands such as Guinness, Stella Artois and Beck’s.

Johnny Stange, Chief Revenue Officer, was formerly a director of sales for the southern California region for Treasury Wine Estates, a major wine wholesaler, where he grew and oversaw annual sales of $250 million. Stange is leading the charge in IONIC’s aggressive sales growth plans across multiple states.

In 2018, IONIC was voted one of the “Top 50 Companies to Work for in Cannabis” by MG Magazine, a publication serving cannabis industry professionals.

IONIC Brands Corp. (OTC: IONKF), closed Wednesday's trading session at $0.1496, off by 5.0159%, on 224,179 volume with 75 trades. The stock's 52-week low/high is $0.035999998/$0.634559988.

Recent News

chart

City View Green Holdings Inc. (CSE: CVGR)

The QualityStocks Daily Newsletter would like to spotlight City View Green Holdings Inc. (CVGR).

City View Green Holdings Inc. (CSE: CVGR), announces that it has negotiated debt settlements with arm's length creditors. Pursuant to the debt settlement agreements, the Company has settled aggregate debt of $580,019 outstanding as at July 24, 2019, in consideration for which it will issue 2,693,460 common shares at a deemed price of $0.15 per share ($404,019) and 977,778 common shares at a deemed price of $0.18 per share ($176,000). When issued, these shares will be subject to a 4 month hold period in accordance with applicable securities laws.

City View Green Holdings Inc.'s (CSE: CVGR) (formerly Icon Exploration Inc.) primary objective is to create a well-diversified company focused on assessing and potentially acquiring targets in the cannabis industry. Icon Exploration recently signed a formal share exchange agreement relating to its proposed acquisition of privately held City View Green (“CVG”), a vertically integrated cannabis company incorporated under the laws of Ontario, Canada. CVG’s application to Health Canada for an A6ccess to Cannabis for Medical Purposes Regulations (“ACMPR”) license is now at the in-depth review stage of the licensing process.

CVG is preparing a 40,000-square-foot growing facility near Toronto to produce pharmaceutical-grade cannabis once its ACMPR license is granted. About half of the facility will initially be outfitted with state-of-the-art LED lighting, HVAC and dehumidification systems, and automation technologies to optimize the quality, safety and consistency of cannabis production. About 4,000 square feet will be devoted to an extraction laboratory featuring an ultra-efficient CO2 supercritical extraction process with plans to include ethanol extraction technology in the future.

Another 4.3 acres remains available for future construction of up to 125,000 square feet of grow and extraction space. Production plans include producing high quality edible products, distillates, and water-soluble products for the rapidly expanding CBD-infused (cannabidiol) beverage market.

Management

Icon and CVG have assembled a talented team that includes a Master Grower with cannabis-industry experience to manage indoor grow operations and an extraction expert whose expertise in developing and launching new products was honed while working in Washington state’s cannabis sector. Having gained experience in the Washington state market the extraction expert has a number of brand ideas and recreational cannabis products that became popular in the Washington market as well as a number of in-licensing branding opportunities available to CVG. CVG has also negotiated an agreement with a private company seeking 37 retail cannabis licenses in Alberta, Canada, that provides a reciprocal exchange of shares, product, shelf space and distribution lines. Early discussions with various entities in Europe to arrange an off-take agreement for CBD oils and extracts are also underway.

Market Opportunity

The Canadian medical cannabis market has steadily been growing with an average 10 percent increase in patients each month. Now that the Canadian federal government has legalized recreational cannabis for adult users nationwide, analysts project a compound annual growth rate of nearly 78 percent from 2018 to 2021, reaching an estimated $3 billion by 2021, ArcView Market Research reports. One study from Deloitte pegged the potential economic impact of legalized medical and recreational marijuana in Canada – including transportation, licensing fees and security – at more than $22 billion over the coming years. Health Canada’s most recent data show that sales of cannabis extracts grew 961 percent in the second quarter of 2017, compared to an 89 percent increase in growth of dried cannabis during the same period.

City View Green Holdings Inc. (CSE: CVGR), closed Wednesday's trading session at $0.125, off by 3.85%, on 32,000 volume. The average volume for the last 3 months is 135,016 and the stock's 52-week low/high is $0.094999998/$0.465000003.

Recent News

chart

Golden Developing Solutions, Inc. (DVLP)

The QualityStocks Daily Newsletter would like to spotlight Golden Developing Solutions, Inc. (DVLP).

Golden Developing Solutions Inc. (OTC: DVLP) is showing exponential growth with its multitiered strategy working in the CBD, hemp and cannabis spaces. The strategy includes a diverse focus on online product sales, acquisitions, manufacturing, product branding and plans for the development of a 25,000-square-foot production facility in Denver, Colorado (http://nnw.fm/o7F4V). Also today, the company was featured in an exclusive broadcast from NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution, which allows investors to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. 

Golden Developing Solutions, Inc. (DVLP), an emerging leader in ancillary software and the cannabidiol (CBD) products marketplace, provides business services and/or products supporting the cannabis industry including an online retail business for CBD, hemp oil and health/wellness related products.

Global acceptance of cannabis and related CBD products continues to increase as North America advances toward favorable legislation. Canada legalized recreational cannabis in October 2018, and the United States has 30 states and the District of Columbia allowing either recreational or medical cannabis, or both. Voters in four additional U.S. states will consider marijuana initiatives on the November 2018 ballot. The global legal cannabis market is projected to reach USD$146 billion by the end of 2025, with a greater acceptance of medical cannabis products as a driving factor, according to Grand View Research.

DVLP recently acquired “Where’s Weed” (Layer Six Media LLC DBA “Where’s Weed”) and its primary asset, WheresWeed.com. Where’s Weed is an American cannabis technology company known for connecting medical and recreational cannabis users with trusted local marijuana businesses in their communities. As a rapidly growing community-based online resource for cannabis consumers with a host of user-friendly services, Where’s Weed offers a sophisticated mobile app with strong traction and powerful growth potential as the North American legal cannabis market continues to expand exponentially.

WheresWeed.com has a large and expanding reach with nearly 3 million pageviews per month. In addition, the WheresWeed mobile app, available in both iOS and Android, has been downloaded over 80,000 times, proving to be complementary to DVLP’s objective to capitalize on the massive growth curve in the marijuana space.

“The huge flood of new growers and producers is likely to create oversupply in the near term, narrowing margins for major producers,” says DVLP CEO Stavros Triant. “However, this should actually increase the net number of new consumers in the marketplace, further reinforcing the enormous growth potential for hub service providers in the space that are situated on high-traffic internet real estate, which is exactly how we view the Where’s Weed property.”

The company’s move into the lucrative C-store snack market was solidified with a material purchase order for CBD oils from a major distributor specializing in the snack foods and accessories to the convenience store and gas station market. The order represents significant progress as DVLP gears up its ready-made snack distribution strategy for its CBD products.

“We are extremely excited about the launch of our CBD product line with this distributor,” Triant states. “The C-Store strategy dovetails perfectly with our direct marketing strategy through our primary online retail channel, and we have indications from the distributor that, if this initial test order goes well, successive Purchase Orders could be significant and underpin strong sales growth in Q1 2019.”

Golden Developing Solutions, Inc. (DVLP), closed Wednesday's trading session at $0.0129, off by 0.769231%, on 521,600 volume with 16 trades. The average volume for the last 3 months is 1,574,325 and the stock's 52-week low/high is $0.0081/$0.14.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.